Drugs / 4SCAR-PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03185468 | Aug 2025 → Dec 2028 expected | urinary bladder cancer, urothelial carcinoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03185468 ↗ |
| Action | Deplete | “can recognize and kill tumor cells” NCT03185468 ↗ |
| Modality | Cell therapy | “4SCAR-PSMA T cells” NCT03185468 ↗ |